Valuation: Janux Therapeutics, Inc.

Market Cap 1.06B 945M 878M 799M 1.5B 100B 1.53B 10.55B 4.13B 52.33B 3.97B 3.89B 167B P/E 2026 *
-9.98x
P/E 2027 * -6.54x
Enterprise Value 160M 143M 133M 121M 227M 15.14B 231M 1.59B 623M 7.9B 600M 587M 25.28B EV / Sales 2026 *
5.43x
EV / Sales 2027 * 38.2x
Free-Float
99.01%
Yield 2026 *
-
Yield 2027 * -
1 day+1.11%
1 week-6.38%
Current month+0.23%
1 month+5.35%
3 months+8.05%
6 months+15.16%
Current year+25.51%
1 week 16.84
Extreme 16.84
18.6
1 month 15.75
Extreme 15.75
19.18
Current year 12.12
Extreme 12.12
20.31
1 year 12.12
Extreme 12.12
35.34
3 years 5.65
Extreme 5.65
71.71
5 years 5.65
Extreme 5.65
71.71
10 years 5.65
Extreme 5.65
71.71
Manager TitleAgeSince
Chief Executive Officer 67 2017-05-31
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer 57 2020-12-31
Director TitleAgeSince
Director/Board Member 64 2021-03-17
Director/Board Member 55 2021-03-17
Director/Board Member 40 2021-02-28
Date Insider Type Main position Quantity % Market Cap. Importance
7/31/26 Don

Founder

-123,840 0.2061%
7/8/26 Exercice

Founder

14,000 0.0233%
6/2/26 Sell

Executive/Senior Manager

-4,059 0.0068%
Change 5-day change 1-year change 3-year change Capi.($)
+1.11%-6.38%-38.76%+98.17% 1.06B
+0.21%-4.63%+55.34%+71.32% 68.98B
+0.03%+4.17%+6.69%+61.45% 53.15B
-0.05%+5.49%+10.11%+41.66% 50.83B
+3.45%+4.70%+33.44%+35.96% 44.61B
-2.20%+0.61%+281.88%+532.76% 40.57B
+6.43%+6.84%+18.32%+109.23% 42.53B
+1.28%+1.39%+11.69%+45.10% 30.95B
-0.90%-10.49%+31.48%-1.63% 25.44B
+1.74%-2.02%-13.55%-12.92% 22.66B
Average +1.11%+0.76%+39.66%+98.11% 38.08B
Weighted average by Cap. +1.07%+2.31%+50.44%+103.29%

Financials

2026 *2027 *
Net sales 29.42M 26.26M 24.41M 22.2M 41.77M 2.79B 42.53M 293M 115M 1.45B 110M 108M 4.65B 8.1M 7.23M 6.72M 6.11M 11.5M 767M 11.71M 80.71M 31.58M 400M 30.39M 29.75M 1.28B
Net income -107M -95.66M -88.9M -80.87M -152M -10.15B -155M -1.07B -418M -5.3B -402M -394M -16.95B -178M -159M -147M -134M -252M -16.83B -257M -1.77B -693M -8.78B -667M -653M -28.1B
Net Debt -899M -802M -746M -678M -1.28B -85.15B -1.3B -8.96B -3.51B -44.43B -3.37B -3.3B -142B -750M -669M -622M -566M -1.06B -71B -1.08B -7.47B -2.92B -37.05B -2.81B -2.75B -119B
Projected Income Statement - Annual - Janux Therapeutics, Inc.
Logo Janux Therapeutics, Inc.
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed three bispecific platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). Its TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain. Its TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and others.
Employees
113
Date Price Change Volume
26-10-15 US$17.32 +1.11% 546,901
26-10-14 US$17.13 -0.29% 614,665
26-10-13 US$17.18 -5.34% 794,897
26-10-12 US$18.15 -1.31% 802,988
26-10-09 US$18.39 -0.59% 1,172,965
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Janux Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
17.32USD
Average target price
36.24USD
Spread / Average Target
+109.21%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Janux Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. JANX Stock